Overview
Cullinan Q3 net loss increases to $50.6 mln compared to last year
Operating income for Q3 beats analyst expectations
Company discontinues CLN-619 and CLN-617 programs based on clinical data review
Outlook
Cullinan plans to share initial CLN-978 data in autoimmune diseases in H1 2026
Company expects cash runway to extend into 2029
Cullinan discontinues CLN-619 and CLN-617 programs
Result Drivers
Research and development expenses were $42.0 million for the third quarter of 2025, compared to $35.5 million for the same period in 2024
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$50.61 mln
Q3 Operating Income
Beat
-$55.60 mln
-$63.29 mln (10 Analysts)
Q3 Cash & Investments
$475.50 mln
Q3 Operating Expenses
$55.60 mln
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Cullinan Therapeutics Inc is $24.00, about 69.5% above its November 5 closing price of $7.31
Press Release: ID:nGNXb39c8n
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
